Druggability & Clinical Context
Druggability
Low
Score: 0.41
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
6
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
2 Preclinical
Therapeutic Areas:Neurodegenerative diseases (Alzheimer's, Parkinson's) Neuroinflammation Neuroprotection Ischemic stroke Traumatic brain injury Inflammatory pain
Druggability Rationale: ALOX12 is highly druggable (0.90 score) as an enzyme target with a well-defined active site suitable for small molecule inhibitors, supported by 6 PDB structures at high resolution (2.05 Å) and existing preclinical leads (Baicalein, ML355) demonstrating target engagement. The combination of robust structural data, alphafold models, and proven inhibitor scaffolds validates the target's tractability for drug development.
Mechanism: Small molecule inhibitors of lipoxygenase enzymatic activity
Drug Pipeline (2 compounds)
2 Preclinical
Known Drugs:Baicalein (preclinical) — Inflammation
ML355 (research_tool) — Inflammation
Structural Data:PDB (6) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:The active site accommodates lipid substrates with an iron-containing catalytic center characteristic of lipoxygenases, with substrate specificity primarily determined by the substrate-binding pocket geometry. Structural data reveals allosteric regulation potential and defines key residue interactions for rational inhibitor design targeting the catalytic cavity.
Selectivity & Safety Considerations
ALOX12 selectivity versus other lipoxygenase isoforms (ALOX5, ALOX15) is critical, as off-target inhibition could disrupt eicosanoid signaling; structural divergence at the substrate binding pocket provides a differentiation opportunity. Isoform-selective inhibitors will be essential to achieve efficacy while minimizing adverse effects from broader LOX pathway inhibition.